Drug Discovery and Development: Acute Respiratory Distress Syndrome (ARDS) Therapeutics

• Publication date: June 2012
• Report size: 74 pages

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome Therapeutics industry . The report identifies the major industry developments shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics industry . The report also provides insights on the prevalent competitive landscape and th...

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome Therapeutics industry . The report identifies the major industry developments shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Acute Respiratory Distress Syndrome Therapeutics segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

The report provides data on the key drivers and challenges of the Acute Respiratory Distress Syndrome Therapeutics industry . Its scope includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) Acute Respiratory Distress Syndrome Therapeutics industry revenues data 2005-2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Acute Respiratory Distress Syndrome Therapeutics industry .
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Acute Respiratory Distress Syndrome Therapeutics therapeutics industry .
- Analysis of key recent licensing and partnership agreements in Acute Respiratory Distress Syndrome Therapeutics industry

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Acute Respiratory Distress Syndrome Therapeutics industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Acute Respiratory Distress Syndrome Therapeutics industry landscape? – Identify, understand and decide.

Therapy Industry in Europe

1 Table of contents

I Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5

II Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Introduction 6
II. 1 Disease Data 6
II. 2 Epidemiology 8
II. 3 Etiology and Pathophysiology 8
II. 4 Signs and Symptoms 10
II. 5 Diagnosis 10
II. 6 Treatment and Management Options 11
II. 6.1 Referral Pathway 12
II. 7 GlobalData Pipeline Report Guidance 12

III ARDS Therapeutics - March ket Characterization 13
III. 1 ARDS Therapeutics March ket Size (2005-2010) – World 13
III. 2 ARDS Therapeutics March ket Forecasted data (2010-2017) – World 14
III. 3 ARDS Therapeutics March ket Size (2005-2010) – The US 15
III. 4 ARDS Therapeutics March ket Forecasted data (2010-2017) – The US 16
III. 5 ARDS Therapeutics March ket Size (2005-2010) – France 17
III. 6 ARDS Therapeutics March ket Forecasted data (2010-2017) – France 18
III. 7 ARDS Therapeutics March ket Size (2005-2010) – Germany 19
III. 8 ARDS Therapeutics March ket Forecasted data (2010-2017) – Germany 20
III. 9 ARDS Therapeutics March ket Size (2005-2010) – Italy 21
III. 10 ARDS Therapeutics March ket Forecasted data (2010-2017) – Italy 22
III. 11 ARDS Therapeutics March ket Size (2005-2010) – Spain 23
III. 12 ARDS Therapeutics March ket Forecasted data (2010-2017) – Spain 24
III. 13 ARDS Therapeutics March ket Size (2005-2010) – The UK 25
III. 14 ARDS Therapeutics March ket Forecasted data (2010-2017) – The UK 26
III. 15 ARDS Therapeutics March ket Size (2005-2010) – Japan 27
III. 16 ARDS Therapeutics March ket Forecasted data (2010-2017) – Japan 28
III. 17 Drivers and Barriers for the ARDS Therapeutics March ket 29
III. 17.1 Drivers for the ARDS Therapeutics March ket 29
III. 17.2 Barriers for the ARDS Therapeutics March ket 29
III. 18 Opportunity and Unmet Need Analysis 30
III. 19 Key Takeaway 30

IV ARDS Therapeutics - Competitive Assessment 31
IV. 1 Overview 31
IV. 1.1 Strategic Competitor Assessment 31
IV. 2 Product Profiles for the Major March keted Products in the ARDS Therapeutics March ket 32
IV. 2.1 Levaquin (levofloxacin) 32
IV. 2.2 Nimbex (cisatracurium besylate) 33
IV. 3 Key Takeaway 33

V ARDS Therapeutics - Pipeline Assessment 34
V. 1 Overview 34
V. 2 Strategic Pipeline Assessment 34
V. 3 Pipeline by Phases of Development 34
V. 3.1 ARDS Therapeutics, Phase III Pipeline 34
V. 3.2 ARDS Therapeutics, Phase II Pipeline 35
V. 3.3 ARDS Therapeutics, Phase I Pipeline 35
V. 3.4 ARDS March ket, Discovery and Pre-Clinical Pipeline 35
V. 3.5 Technology Trends Analytic Framework 36
V. 4 ARDS Therapeutics March ket, Clinical Pipeline by Mechanism of Action 38
V. 5 Key Takeaway 38

VI ARDS Therapeutics - Clinical Trials Mapping 39
VI. 1 Clinical Trials by Region/Country (US, EU5 and Japan) 39
VI. 2 Clinical Trials by Phase 40
VI. 3 Clinical Trials by Trial Status 41
VI. 4 Key Sponsors 42
VI. 5 Top Firms Participating in ARDS Therapeutics Clinical Trials 44

VII Strategic Assessment 45
VII. 1 Key Events Impacting the Future March ket 45
VII. 2 ARDS Therapeutics - Implications for Future March ket Competition 46

VIII ARDS Therapeutics - Future Players 47
VIII. 1 Introduction 47
VIII. 2 Firms Profiles 48
VIII. 2.1 Altor BioSciences 48
VIII. 2.2 Faron Pharmaceuticals, Ltd. 49
VIII. 2.3 Ikaria, Inc. 51
VIII. 2.4 GlaxoSmithKline 52

IX ARDS Therapeutics - Licensing and Partnership Deals 55

X ARDS Therapeutics - Appendix 56
X. 1 March ket Definitions 56
X. 2 Abbreviations 56
X. 3 Research Methodology 57
X. 3.1 Coverage 57
X. 3.2 Secondary Research 57
X. 3.3 Forecasted data ing 58
X. 3.4 Primary Research 60
X. 3.5 Expert Panel Validation 60
X. 4 Contact Us 60
X. 5 Disclaimer 61
X. 6 Bibliography 61

1.1

List of Tables


Data table 1: Lung Pressure In ARDS 6
Data table 2: Clinical Disorders Commonly Associated with ARDS 10
Data table 3: ARDS Therapeutics March ket, Global, Sales (USD Million), 2005–2010 13
Data table 4: ARDS Therapeutics March ket, Global, Forecasted data (USD Million), 2010–2017 14
Data table 5: ARDS Therapeutics March ket, The US, Sales (USD Million), 2005–2010 15
Data table 6: ARDS Therapeutics March ket, The US, Forecasted data s (USD Million), 2010–2017 16
Data table 7: ARDS Therapeutics March ket, France, Sales (USD Million), 2005–2010 17
Data table 8: ARDS Therapeutics March ket, France, Forecasted data s (USD Million), 2010–2017 18
Data table 9: ARDS Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 19
Data table 10: ARDS Therapeutics March ket, Germany, Forecasted data (USD Million), 2010–2017 20
Data table 11: ARDS Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 21
Data table 12: ARDS Therapeutics March ket, Italy, Forecasted data (USD Million), 2010–2017 22
Data table 13: ARDS Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 23
Data table 14: ARDS Therapeutics March ket, Spain, Forecasted data s (USD Million), 2010–2017 24
Data table 15: ARDS Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 25
Data table 16: ARDS Therapeutics March ket, The UK, Forecasted data s (USD Million), 2010–2017 26
Data table 17: ARDS Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 27
Data table 18: ARDS Therapeutics March ket, Japan, Forecasted data (USD Million), 2010–2017 28
Data table 19: ARDS Therapeutics, Phase II Pipeline, 2011 35
Data table 20: ARDS Therapeutics, Phase I Pipeline, 2011 35
Data table 21: ARDS Therapeutics, Preclinical Pipeline, 2011 35
Data table 22: ARDS Therapeutics, Clinical Trials by Country, 2011 39
Data table 23: ARDS Therapeutics, Clinical Trials by Phase, 2011 40
Data table 24: ARDS Therapeutics, Clinical Trials by Status, 2011 41
Data table 25: ARDS Therapeutics, Overall Sponsors, 2011 42
Data table 26: ARDS Therapeutics, Key Sponsors, 2011 43
Data table 27: ARDS Therapeutics, Top Firms Participating in Therapeutics Clinical Trials, 2011 44
Data table 28: Altor BioSciences, Inflammatory and Infectious Diseases, Pipeline, 2011 48
Data table 29: Altor BioSciences, ARDS, Pipeline, 2011 48
Data table 30: Faron Pharmaceuticals, Inflammatory and Infectious Diseases Pipeline, 2011 49
Data table 31: Faron Pharmaceuticals, ARDS Pipeline, 2011 49
Data table 32: Faron Pharmaceuticals, Deals, from 2009 to 2011 50
Data table 33: Ikaria, Inc., CNS Pipeline, 2011 51
Data table 34: Ikaria, Inc., ARDS pipeline, 2011 51
Data table 35: Ikaria, Inc., Deals, from 2009 to 2011 51
Data table 36: GlaxoSmithKline, Respiratory Diseases Pipeline, 2011 53
Data table 37: GlaxoSmithKline, ARDS pipeline, 2011 54
Data table 38: GlaxoSmithKline, Deals, from 2009 to 2011 54
Data table 39: ARDS Therapeutics, Deals, from 2009 to 2011 55

1.2

List of Figures


Chart 1: ARDS Pulmonary Pressure 6
Chart 2: ARDS Affected Lung With Enlarged Alveoli 7
Chart 3: Time Course for the Development and Resolution of ARDS 9
Chart 4: Lung Infected with ARDS 9
Chart 5: ARDS, Treatment Patterns 11
Chart 6: ARDS, Referral Pathway 12
Chart 7: ARDS Therapeutics March ket, Global, Sales (USD Million), 2005–2010 13
Chart 8: ARDS Therapeutics March ket, Global, Forecasted data (USD Million), 2010–2017 14
Chart 9: ARDS Therapeutics March ket, The US, Sales (USD Million), 2005–2010 15
Chart 10: ARDS Therapeutics March ket, The US, Forecasted data (USD Million), 2010–2017 16
Chart 11: ARDS Therapeutics March ket, France, Sales (USD Million), 2005–2010 17
Chart 12: ARDS Therapeutics March ket, France, Forecasted data (USD Million), 2010–2017 18
Chart 13: ARDS Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 19
Chart 14: ARDS Therapeutics March ket, Germany, Forecasted data (USD Million), 2010–2017 20
Chart 15: ARDS Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 21
Chart 16: ARDS Therapeutics March ket, Italy, Forecasted data (USD Million), 2010–2017 22
Chart 17: ARDS Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 23
Chart 18: ARDS Therapeutics March ket, Spain, Forecasted data (USD Million), 2010–2017 24
Chart 19: ARDS Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 25
Chart 20: ARDS Therapeutics March ket, The UK, Forecasted data (USD Million), 2010–2017 26
Chart 21: ARDS Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 27
Chart 22: ARDS Therapeutics March ket, Japan, Forecasted data (USD Million), 2010–2017 28
Chart 23: Opportunity and Unmet Need in the ARDS Therapeutics March ket, 2010 30
Chart 24: ARDS Therapeutics, Strategic Competitor Assessment, 2010 31
Chart 25: ARDS Therapeutics, Pipeline by Phase of Development, 2011 34
Chart 26: ARDS Therapeutics, Technology Trends Analytics Framework, 2011 36
Chart 27: ARDS Therapeutics, Technology Trends Analytics Framework, Description, 2011 37
Chart 28: ARDS Therapeutics, Pipeline by Mechanism of Action (%), 2011 38
Chart 29: ARDS Therapeutics, Clinical Trials by Country, 2011 39
Chart 30: ARDS Therapeutics, Clinical Trials by Phase (%), 2011 40
Chart 31: ARDS Therapeutics, Clinical Trials by Status (%), 2011 41
Chart 32: ARDS Therapeutics, Overall Sponsors (%), 2011 42
Chart 33: ARDS Therapeutics, Key Sponsors (%), 2011 43
Chart 34: ARDS Therapeutics, Global, Clinical Trials by Top Firms, 2011 44
Chart 35: ARDS Therapeutics March ket, Drivers and Barriers, 2011 45
Chart 36: Implications for Future March ket Competition in the ARDS March ket, 2011 46
Chart 37: ARDS Therapeutics March ket, Pipeline by Firms, 2010 47
Chart 38: GlobalData March ket Forecasted data ing Model 59

Companies Mentioned
Altor BioSciences
Faron Pharmaceuticals, Ltd.
Ikaria, Inc.
GlaxoSmithKline